Paul Weiss is a Managing Director at Venture Investors Health Fund in Madison, Wisconsin. See sector focus and contact routes.
Paul Weiss is a Managing Director at Venture Investors Health Fund in Madison, Wisconsin, having joined the firm in 2006 with over 20 years of operating experience in biotech and pharmaceuticals. His investment thesis targets biopharma, diagnostics, and devices with biopharma overlap, focusing on seed and early-stage healthcare companies primarily in the Midwest region. While specific check sizes and lead/follow behavior are not publicly detailed, he actively serves on the boards of multiple portfolio companies including Invenra, Iterion Therapeutics, FluGen, and Madison Vaccines. His notable portfolio also includes Neurovance, which was sold to Otsuka for up to $1 billion, and Aerpio Pharmaceuticals, now Aadi Bioscience. Weiss leverages his prior executive roles at Cardinal Health, 3-Dimensional Pharmaceuticals, and Wyeth-Ayerst to evaluate investment prospects. No distinctive public writing or unique point of view beyond his operational focus is documented in available sources.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Madison when building a target list.
Investors like Paul Weiss · Full investor directory · Investor access · Company funding database